COMPANY PROFILE

Paradigm Therapeutics

Explore full profile

Biopharmaceutical solutions for Epidermolysis Bullosa, offering comprehensive topical treatments for all subtypes

Mount Pleasant, United StatesBiotech & Life Sciences

Valuation $50–100M Last recorded · 2025

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Paradigm Therapeutics

Paradigm Therapeutics Inc. is a biopharmaceutical company focused on addressing the unmet medical needs of patients with serious, life-threatening diseases. The company recently acquired the worldwide rights to SD 101, a topical treatment designed for all subtypes of Epidermolysis Bullosa (EB), a rare genetic disorder characterized by fragile skin and poor wound healing. Paradigm Therapeutics operates in the niche market of rare genetic disorders, providing solutions that go beyond palliative care. The business model revolves around the discovery, development, and delivery of specialized therapies, generating revenue through the commercialization of these treatments. Paradigm Therapeutics serves a global clientele, including patients, healthcare providers, and research institutions, aiming to improve patient outcomes and quality of life. The company is committed to advancing clinical trials and research studies, offering patient resources and ongoing support.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Headquarters: Mount Pleasant, United States
Employees: 7
Open positions: None listed
Dealroom signal: 0.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Genetics and genomics, Biotech and Pharma, AI Drug Discovery, DT and LS
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	May 2025	$13M	$50M	Eshelman Ventures	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Paradigm Therapeutics website traffic

Latest recorded traffic for Paradigm Therapeutics is 70 monthly website visits, down 96.7% over the last three months.

Latest monthly visits70 3-month web change-96.7%

Monthly website visitsApr 2025–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PBProxima BioFormerly VantAI. Proximity therapeutics hijacking cellular machinery for protein degradation	New York City, United States	Operational	77	$80M	$320M
NANorVita Med AsPatient-derived organoid and neuron models for drug discovery and precision medicine in mitochondrial disease therapy	—	Operational
DLDante LabsGenomic and precision medicine solutions, from whole genome sequencing and interpretation to data-driven drug discovery	Hendersonville, United States	Operational
PBPrecision BioPharmaPioneering drug development with AI-driven Adaptive Translational Research for rapid discovery and regulatory success	Stockholm, United States	Operational
SBSidera BioAdvancing genetic discoveries to enhance precision medicine through large-scale data analyses	Cambridge, United States	Operational
XBXanadu BioPioneering cystic fibrosis treatment through small molecules and gene editing	Lower Merion Township, United States	Operational
ETEtiomeBiostaged Medicines targeting disease progression with stage-specific therapies for improved health outcomes	Cambridge, United States	Operational
RBRadical BioHigh-resolution mass spectrometry for precise disease-specific protein structure analysis in drug discovery	Madison, United States	Operational